Feng (Frank) Li, Ph.D.

Feng (Frank) Li, Ph.D.

President and Founder

Feng (Frank) Li, Ph.D.

Feng (Frank) Li, Ph.D.

President and Founder

Feng (Frank) Li, Ph.D., is President of Alliance Pharma. He obtained his Ph.D. degree in Bioanalytical Chemistry jointly from Concordia University and the National Institute of Scientific Research (Canadian Doping Control Center) in Montreal, Canada. Subsequently, Dr. Li did his post-doctoral fellowship at the Biomedical Mass Spectrometry Facility at the Mayo Clinic in Rochester, Minnesota.

Furthermore, Dr. Li has an M.Sc. degree in Natural Product Chemistry and a B.S. in Pharmacy. He has held leadership roles in the Department of Drug Discovery Metabolism at Phoenix International Life Sciences, Inc., a major CRO at the time in Montreal, Canada, which was later acquired by MDS Pharma Services; in the Drug Analysis group in the Department of Drug Metabolism and Pharmacokinetics (DMPK) at GlaxoSmithKline; and in the Drug Metabolism group in the Department of Drug Safety and Disposition at Cephalon, Inc. Dr. Li has extensive DMPK experience in discovery and developmental phases of drug development.

With more than 25 years in the pharmaceutical biotechnology, and CRO industry, he is well versed in bioanalytical techniques for both qualitative (drug metabolite identification) and quantitative (PK/TK) drug analysis, and has published numerous articles in the area of drug metabolite identification and quantitation.

Michael Zhang, Ph.D.

Michael Zhang, Ph.D.

Vice President, Quality and Co-founder

Michael Zhang, Ph.D.

Michael Zhang, Ph.D.

Vice President, Quality and Co-founder

Michael Zhang, Ph.D., serves as Vice President of Quality at Alliance Pharma. Prior to his current positon, Dr. Zhang was the Vice President of Operations. Dr. Zhang has extensive experience in Analytical Chemistry, Computer Science, and Quality and Regulatory Compliance. His expertise includes development and validation of LC-MS/MS methods for analyses of biological samples and pesticide/herbicide residue samples, FDA/EPA/OECD GLP compliance, quality management systems, analytical instrumentation, software development, information technology, and computerized systems validation.

Before joining Alliance, Dr. Zhang was an Associate Director at Keystone Analytical Laboratories (a subsidiary of former PharmaNet Development Group, Inc.). Dr. Zhang has developed numerous challenging LC-MS/MS methods for biological and agrochemical analyses, built up the IT infrastructure, and established GLP compliant laboratories and 21 CFR Part 11 compliant computerized systems at several companies.

Dr. Zhang has also worked as a software engineer at Motorola (Chicago, IL) and a Programmer Analyst at Affina (Peoria, IL). Dr. Zhang earned his Ph.D. degree in Analytical Chemistry and M.Sc. degree in Computer Science, both from the University of Missouri-Rolla (Rolla, MO). Dr. Zhang also holds an M.Sc. degree in Analytical Chemistry and a B.S. degree in Chemistry from the University of Science and Technology of China (Hefei, Anhui).

Zhiyang Zhao, Ph.D.

Zhiyang Zhao, Ph.D.

Sr. Vice President, Corporate Development and Chief Scientific Officer

Zhiyang Zhao, Ph.D.

Zhiyang Zhao, Ph.D.

Sr. Vice President, Corporate Development and Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Alliance Pharma. Dr. Zhao has over 25 years of pharmaceutical industry experience with special focus on metabolic and pharmacokinetic properties of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Alliance Pharma, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade.

Dr. Zhao’s extensive experience spans the entire drug discovery and development process (discovery, development, and in-/out-licensing) in oncology, metabolic, antiviral, CNS, and inflammatory diseases. Dr. Zhao’s contributions and accomplishments of integrating in vitro and in vivo ADMET (absorption, distribution, metabolism, excretion, and toxicity) information to optimize drug candidate properties are documented in over 50 peer‑reviewed scientific publications and patents in the areas of new drug targets, drug metabolism, pharmacokinetics, and toxicology.

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and disposition. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia.

Colin Barry, Ph.D.

Colin Barry, Ph.D.

Vice President, Technology

Colin Barry, Ph.D.

Colin Barry, Ph.D.

Vice President, Technology

Colin Barry, Ph.D., who serves as Head of the Bioanalysis department and the Sr. Director of Large Molecule Bioanalysis, brings more than a decade of experience in LC-MS analysis of proteins and peptides.

Prior to joining Alliance, Dr. Barry led the Biologics group at SGS, a multinational CRO headquartered in Switzerland. Dr. Barry has also worked for the U.S. Food and Drug Administration (FDA) performing applied research and method development for the analysis and characterization of biopharmaceuticals. While at the FDA, Dr. Barry was awarded the Commissioner’s Special Citation for his work with the Necrotizing Enterocolitis Response Group. Dr. Barry earned his doctorate degree in Chemistry from Wake Forest University in Winston-Salem, North Carolina. Subsequently, he did a postdoctoral fellowship at the University of Pennsylvania Perelman School of Medicine Center for Cancer Pharmacology in the laboratory of Dr. Ian Blair.

Dr. Barry’s research has been published in multiple scientific journals including Blood, Journal of Proteome Research, and the Journal of the American Chemical Society. In addition, he is an active member of the American Chemical Society and the American Society for Mass Spectrometry. In 2014, Dr. Barry was admitted to the U.S. Patent Bar.

Hong Chen, Ph.D.

Hong Chen, Ph.D.

Scientific Director, Biopharmaceutical Services

Hong Chen, Ph.D.

Hong Chen, Ph.D.

Scientific Director, Biopharmaceutical Services

Hong Chen, Ph.D., serves as Scientific Director of the Biopharmaceutical Services department at Alliance Pharma. Hong has more than a decade of experience in immuno-assay development, validation and sample analysis in support of multiple clinical and preclinical studies.

Prior to joining Alliance, Dr. Chen was a Sr. Scientist at Reaction Biology Corporation and a Principal Scientist at GlaxoSmithKline. Dr. Chen earned her doctorate degree in Molecular and Cellular Biology from Temple University in Philadelphia, Pennsylvania. Subsequently, she did a postdoctoral fellowship at the University of Pennsylvania, Perelman School of Medicine in the laboratory of Dr. Mark Kahn.

Dr. Chen has published numerous scientific papers in the field of immunology, virology, molecular biology, and vascular biology in multiple scientific journals including Gene and Development, Proc. Natl. Acad. Sci. USA, Blood, Journal of Biologic Chemistry, and Molecular Cell Biology.

Ryan Klein, Ph.D.

Ryan Klein, Ph.D.

Sr. Director, Business Development

Ryan Klein, Ph.D.

Ryan Klein, Ph.D.

Sr. Director, Business Development

Ryan Klein, PhD, serves as Director of Business Development since joining Alliance Pharma in May 2018. Dr. Klein has more than 20 years of experience in the pharmaceutical industry developing both oral and topical dosage forms for a range of indications. Ryan earned his bachelor’s degree in Chemistry from Wake Forest University in Winston-Salem, North Carolina, and earned his doctoral degree in Pharmaceutical Sciences from the School of Pharmacy at the University of North Carolina at Chapel Hill.

Dr. Klein began his career at GlaxoSmithKline, where he was an integral component of their drug discovery organization providing drug metabolism and pharmacokinetic expertise to project teams. He was instrumental in the development and implementation of a number of in vitro and in situ ADME models to assess drug absorption, metabolism, and disposition. After leaving GSK, Dr. Klein joined Tergus Pharma, a CRO providing topical R&D services to the pharmaceutical industry. At Tergus, Ryan filled various leadership positions as the company grew from five employees to approximately seventy five over a seven year period, including Head of Research & Development and Head of In Vitro Sciences.

Dr. Klein’s areas of expertise include drug permeability, absorption and metabolism in the gastrointestinal tract, liver and skin, intestinal drug transporters, and the anatomy, physiology, and pharmacology of the skin and GI tract. He also has a strong analytical background with extensive experience developing and validating in vitro release testing methods for semi-solid dosage forms, as well as assay and impurities methods, and bioanalytical methods.

Ryan has authored & co-authored numerous scientific publications and patents, and serves as a member of several pharmaceutical research focus and discussion groups.
Outside of science, Ryan enjoys golf and running, usually while chasing his two children. Ryan is located in Raleigh, NC just outside of Research Triangle Park.

Contact Ryan Klein directly at  919-801-3146or via email rklein@alliancepharmaco.com

Xianrong (Jenny) Wei

Xianrong (Jenny) Wei

Director, Business Development

Xianrong (Jenny) Wei

Xianrong (Jenny) Wei

Director, Business Development

Xianrong (Jenny) Wei serves as Director of Business Development, managing Alliance Pharma’s West Coast region. She has over 19 years of experience working in the pharmaceutical and consumable industries. Her work encompassed pharmaceutical, biopharmaceutical, clinical, food safety and environmental control sectors under GLP/GCP/GMP and/or at discovery level.

Ms. Wei has extensive experience in leading and supporting bioanalytical method development and validation, regulated bioanalysis, automation processes and chromatography separations through major companies such as Phenomenex, Merck, Schering-Plough and GlaxoSmithKline.

She previously served as a key player in the marketing department for Phenomenex’s Team China, helping pursue business stategies, business development and customer relationship management during their international expansion. Her scientific work has been published and presented at ASMS, Pittcon, AOAC and in the Bioanalysis Journal.  Jenny is located in Los Angeles, CA.

Contact Jenny Wei directly at  610-606-8313or via email jwei@alliancepharmaco.com

hs_qimin

Qimin Chao, Ph.D.

Director, Business Development

hs_qimin

Qimin Chao, Ph.D.

Director, Business Development

Qimin Chao received a Bachelor of Science in Biology from Nachang University (formerly Jiangxi University), in Nanchang, China in 1982, and his M.S. in Microbial Genetics from Fudan University in Shanghai, China in 1985.

He came to the United States as a CUSBEA scholar and received his Ph.D. in Biochemistry and Molecular Biology from the University of California at Davis in 1993. He was an NIH postdoctoral fellow at the University of Pennsylvania in the laboratory of Dr. Joseph Ecker (Currently at Salk Institute, San Diego, CA).

In 2000, Dr. Chao joined Morphotek Inc. (acquired by Eisai Inc. in 2007) as its first senior scientist and was promoted to Director of Lead Discovery. He was primarily responsible for leading antibody generation and cloning before starting his own consulting business in 2018. In 2019, Dr. Chao joined Alliance Pharma as Director, Business Development. Qimin is located in Philadelphia, PA.

Contact Qimin Chao directly at  610-945-8253or via email qchao@alliancepharmaco.com

Aihua Liu, Ph.D.

Aihua Liu, Ph.D.

Director, Bioanalysis

Aihua Liu, Ph.D.

Aihua Liu, Ph.D.

Director, Bioanalysis

Aihua Liu, Ph.D., is the Director of Bioanalysis in Alliance Pharma. She holds a Ph.D. in Analytical Chemistry, an M.S. in Pharmaceutical Chemistry, and a B.S. in Pharmacy. She has five years of postdoctoral training in Biochemistry. Prior to joining Alliance Pharma, she was the Director of R&D and Chromatography in Dyad Labs after serving as the Team Lead of the bioanalytical method development group at Covance in Salt Lake City.


Dr. Liu has more than 15 years of experience in bioanalysis. Her research interests focus on novel analytical method development/validation and its sample analysis in bioanalysis of small molecules, oligonucleotides, ADC, lipids, DBS et al. In the previous company, Dr. Liu has successfully established a chromatography lab and team, which significantly increased the company’s revenue and profit.


Dr. Liu has authored more than 65 peer-reviewed publications, abstracts, conference posters/oral presentations and book chapters in the areas of analytical chemistry and herbal medicine. She is an active member of the American Association of Pharmaceutical Scientists (AAPS), the American Society of Mass Spectrometry (ASMS), the American Organization of Analytical Chemists (AOAC), and the International Conference on the Science of Botanicals (ICSB).

hs_chunying

Chunying Gao, Ph.D.

Associate Director, Drug Metabolism

hs_chunying

Chunying Gao, Ph.D.

Associate Director, Drug Metabolism

Dr. Gao serves as an Associate Director in the Drug Metabolism Department at Alliance Pharma, responsible for new method and assay development in drug metabolism and transporter studies, providing scientific support for challenging research projects, as well as overseeing routine drug screening studies.

Chunying has more than 10 years’ experience in the field of DMPK, with special expertise in drug transporters and transporter-related drug-drug interactions. Dr. Gao received her PhD degree in pharmaceutical analysis from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. She continued to do research on efflux drug transporters in Dr. Susan Cole’s lab at Queen’s University in Canada. Subsequently, she joined Dr. Qingcheng Mao’s lab in the University of Washington, and focused her research on the role of drug transporters in the drug ADME processes.

Dr. Gao has published 14 peer-reviewed scientific publications in the DMPK area. She is also serving as an editor assistant for the Asian Journal of Pharmaceutical Sciences.

Yong Lin

Yong Lin

Director, Biopharmaceutical Services

Yong Lin

Yong Lin

Director, Biopharmaceutical Services

Yong Lin has served as a scientist and significant contributor to the Biopharmaceutical Services department at Alliance Pharma since 2010, responsible for method development and validation to support pharmacokinetic and immunogenicity studies. As a Principal Investigator at Alliance, Yong leads various projects and plays a key role interacting with clients, as well as designing and executing experiments.

Yong has more than 20 years of experience in the pharmaceutical industry. Prior to joining Alliance Pharma, he spent time at Bausch & Lomb, MDS Pharma, and IBEX Pharmaceuticals supporting various stages of Research and Development by executing cell-based and immune-assays using various platforms.

Yong earned a Masters in Veterinary Medicine from South China Agricultural University, as well as a Masters in Cell Biology from McGill University in Canada. Throughout his career, Yong has published a number of research articles in peer reviewed journals, and co-authored various patents.

Tatiana Field

Tatiana Field

Sr. Manager, Quality Control

Tatiana Field

Tatiana Field

Sr. Manager, Quality Control

Tatiana Field is a peerless champion of quality and continual improvement at Alliance Pharma. Tatiana brings over 15 years of pharmaceutical experience to the company (Phases 1 through 4), including regulatory medical/scientific writing and quality expertise.

Prior to joining Alliance, she facilitated the startup of the clinical writing group at Cephalon, Inc., in West Chester, Pennsylvania. During her 10-year tenure, she led the planning and execution of regulatory documents, including for Cephalon’s first multinational commercial drug approval.

Tatiana’s startup experience also includes the creation of the scientific writing department at XenoBiotic Laboratories, Inc., a contract research organization providing bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries. The company was subsequently acquired by WuXi PharmaTech.

Tatiana earned her Bachelor of Science degree from University of Rochester, Rochester, New York, in Neuroscience, with a minor in Psychology. In addition to English, Tatiana is fluent in Russian, Spanish, and French. When she is not reading the dictionary or technical journals, she enjoys digging in her garden, theorem painting, and knitting.

Steve Gorman

Steve Gorman

Auditor, Quality Assurance

Steve Gorman

Steve Gorman

Auditor, Quality Assurance

Steve Gorman joined Alliance Pharma in May 2018 as a Project Manager, and currently serves as an auditor in the Quality Assurance Unit.  He provides general support of the Quality Management System at and holds primary responsibility for hosting client audits and regulatory agency inspections.

Mr. Gorman has over 30 years of experience in the pharmaceutical industry in regulated small molecule bioanalytical.  He has supported preclinical discovery programs, GLP pre-clinical IND enabling studies, and clinical studies from Phase I through Phase IV.  Mr. Gorman’s experience includes hands-on method development and sample analysis in the laboratory, as well as management and oversight of a regulated bioanalytical laboratory.  He brings a unique perspective to Alliance Pharma, having managed the outsourcing of bioanalytical studies in the United States and in the EU for over 25 years at a large pharmaceutical company. His attendance at all Crystal City Workshops on Bioanalytical Method Validation since 2000 (CC II through VI), and at key meetings such as WRIB, are the basis for his expertise in understanding the requirements of regulated bioanalysis.

Mr. Gorman holds a degree in Biochemistry from the Pennsylvania State University.  He has authored or co-authored 10 journal articles.  He has also served on the Steering Committee of the Delaware Valley Drug Metabolism Discussion Group for 26 years.

Lisa Leaf

Lisa Leaf

Project Manager

Lisa Leaf

Lisa Leaf

Project Manager

Lisa Leaf first joined Alliance Pharma in 2014 as an analyst in the Drug Metabolism team developing expertise implementing in vitro ADME assays to support Drug Discovery.

In 2015 Lisa’s role expanded to include project coordination activities in support of all drug metabolism studies, and in 2016 Lisa became the primary Project Manager supporting each of the major functional departments at Alliance. Her key responsibilities include facilitating communication with customers, maintaining key relationships, drafting and review of contracts and proposals, coordinating departmental resources, managing project timelines, and tracking and projecting company revenue.

Prior to joining Alliance, Lisa held two internship positions at Pfizer and GlaxoSmithKline in Global Labelling Management and DMPK, respectively. Lisa earned her B.Sc. from West Chester University just outside of Philadelphia PA in Pharmaceutical Product Development in 2014.